Welcome to our dedicated page for Tvardi Therapeutics news (Ticker: TVRD), a resource for investors and traders seeking the latest updates and insights on Tvardi Therapeutics stock.
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company whose news flow centers on the development of oral small molecule therapies targeting STAT3 for fibrosis-driven diseases and oncology indications. Company press releases consistently describe Tvardi as focused on STAT3, a transcription factor it identifies as a central mediator of fibrotic signaling pathways and as involved in cancer cell survival and immune evasion.
News updates for TVRD commonly cover progress in clinical trials of its lead STAT3 inhibitor TTI-101 and its next-generation STAT3 inhibitor TTI-109. Tvardi has issued detailed announcements on the REVERT IPF Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis, including completion of enrollment, preliminary data indicating that the study did not meet its goals, and subsequent analyses examining fibrosis scores, inflammatory markers such as IL-6, and pulmonary function measures like Forced Vital Capacity. Additional news highlights the REVERT Liver Cancer Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma and the initiation and progress of a healthy volunteer study of TTI-109.
Investors and followers of TVRD news can also expect regular financial and business updates, including quarterly results, cash runway disclosures, and commentary on upcoming clinical milestones. Tvardi frequently announces participation in healthcare and biotechnology investor conferences, such as events hosted by J.P. Morgan, Piper Sandler, Jefferies, Cantor and BTIG, where management provides corporate presentations and engages with investors.
This news page aggregates Tvardi’s press releases and related coverage so readers can track clinical trial developments, data readouts, regulatory milestones, and corporate communications related to its STAT3-targeted programs. For those monitoring TVRD stock, the news stream offers insight into how Tvardi’s clinical and corporate activities evolve over time.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company, reported its Q2 2025 financial results and business updates. The company completed enrollment in its REVERT IPF Phase 2 trial of TTI-101 for idiopathic pulmonary fibrosis, with topline data expected in Q4 2025. Tvardi also submitted an IND for TTI-109 and completed a merger with Cara Therapeutics to become publicly traded.
Financial highlights include $41.0 million in cash and equivalents, a net income of $4.2 million compared to a $7.0 million loss in Q2 2024, primarily due to a $12.8 million remeasurement gain on Convertible Notes. R&D expenses decreased to $5.8 million, while G&A expenses increased to $3.1 million. The company's cash runway is expected to fund operations into Q4 2026.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral STAT3-targeting therapies for fibrosis-driven diseases, will participate in the BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat on July 30, 2025 at 4:40 PM ET and conduct one-on-one investor meetings.
Investors can access the fireside chat webcast through Tvardi's investor website, with the replay available for approximately 60 days after the conference.
Tvardi Therapeutics (NASDAQ: TVRD) has completed enrollment in its Phase 2 clinical trial of TTI-101 for treating idiopathic pulmonary fibrosis (IPF). The REVERT IPF trial is a randomized, double-blind, placebo-controlled study evaluating TTI-101, an oral small molecule STAT3 inhibitor. The trial focuses on safety and lung function (FVC) endpoints, with topline data expected in Q4 2025.
TTI-101's unique dual mechanism of action inhibits STAT3-driven proliferation while activating T-cells, which has shown promise in preclinical studies by reducing lung fibrosis and restoring lung function. IPF is a chronic, progressive lung disease with poor prognosis, where current treatments only slow progression without halting or reversing fibrosis.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, has announced its participation in two upcoming investor conferences. The company will join the Piper Sandler 3rd Annual Virtual Lung Symposium on May 27, 2025, at 11:30 AM ET for a fireside chat. Additionally, Tvardi will present at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 11:40 AM ET, which will include a corporate presentation and investor meetings. The Jefferies presentation will be available via webcast on Tvardi's Investors' website with a 60-day replay period.
Tvardi Therapeutics (NASDAQ: TVRD) announced its upcoming presentation at the American Thoracic Society 2025 Annual Conference in San Francisco. The presentation will highlight research on their STAT3 inhibitor, TTI-101, for treating idiopathic pulmonary fibrosis (IPF). Key findings show that ~60% of IPF-associated dysregulated genes are not addressed by current approved therapies (nintedanib and pirfenidone), termed the "IPF therapeutic gap." Research using single-cell RNA sequencing identified STAT3 as a dominant regulatory transcription factor in IPF. Notably, TTI-101 showed greater repression of genes within alveolar fibroblasts compared to existing treatments and demonstrated ability to downregulate genes involved in extracellular matrix production, including collagen genes.